MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of shares...
    • Prepaid expenses and other curre...
Negative Cash Flow Breakdown
    • Purchase of short-term investmen...
    • Accounts payable and other curre...
    • Stock-based compensation
    • Issuance costs
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,794,863
-2,541,070
-8,112,450
-2,975,117
Stock-based compensation
-64,283
227,180
785,814
150,614
Change in fair value of convertible promissory notes
-
-
-2,306,842
1,941,124
Warrant repricing
0
410,154
-
-
Prepaid expenses and other current assets
-249,085
-119,319
-203,386
357,997
Accounts payable and other current liabilities
-317,573
-5,225,576
1,764,780
1,084,078
Operating lease right-of-use asset and liability, net
-
-
-199
-597
Net cash used in operating activities
-1,927,634
-7,009,993
-3,190,513
-2,567,427
Purchase of short-term investments
4,000,000
-
-
-
Proceeds from issuance of convertible promissory notes
-
-
0
0
Net cash used in investing activities
-4,000,000
-
-
-
Proceeds from issuance of shares of common stock and warrants
12,000,000
-
0
2,339,169
Proceeds from issuance of preferred stock
-
-
6,000,000
-
Proceeds from exercise of pre-funded warrants
-
-
1,754
154
Issuance costs
16,181
-
129,252
103,958
Net cash provided by financing activities
11,983,819
-
5,872,502
2,235,365
Net change in cash and cash equivalents
6,056,185
-7,009,993
2,681,989
-332,062
Cash and cash equivalents, beginning of period
1,497,635
8,507,628
5,825,639
5,786,753
Cash and cash equivalents, end of period
7,553,820
1,497,635
8,507,628
5,825,639
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofshares of common stock...$12,000,000 (195.73%↑ Y/Y)Net cash provided byfinancing activities$11,983,819 (27.00%↑ Y/Y)Canceled cashflow$16,181 Net change in cashand cash...$6,056,185 (1532.62%↑ Y/Y)Canceled cashflow$5,927,634 Issuance costs$16,181 (-95.19%↓ Y/Y)Prepaid expenses andother current assets-$249,085 (69.69%↑ Y/Y)Net cash used ininvesting activities-$4,000,000 Net cash used inoperating activities-$1,927,634 (78.74%↑ Y/Y)Canceled cashflow$249,085 Purchase of short-terminvestments$4,000,000 Net loss-$1,794,863 (81.61%↑ Y/Y)Accounts payable andother current...-$317,573 (-123.81%↓ Y/Y)Stock-based compensation-$64,283 (-115.25%↓ Y/Y)

Indaptus Therapeutics, Inc. (INDP)

Indaptus Therapeutics, Inc. (INDP)